Similar results were obtained by suppressing BCL9 function with ectopic expression of miR-30–5p [79] or treatment with a BCL9-derived peptide that specifically disrupts the BCL9/β–catenin interaction [80], supporting the notion that BCL9 overexpression mediates Wnt-driven tumorigenesis in MM. Here, BCL9 is linked to Miyoshi myopathy.